GSK’s Arexvy receives approval in Europe for expanded use in all adults 18 years and older

GSK announces that Arexvy has been approved by the European Commission for use in adults aged 18 years and older. Arexvy was the first RSV vaccine authorised in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV. It was previously approved in adults aged 60 years and above, as well as in those aged 50 to 59 years who are at increased risk for RSV disease.

Sanjay Gurunathan, GSK Head of Vaccines and Infectious Diseases Research and Development, said: “This approval helps protect all adults aged 18 and older in Europe against RSV, a potentially serious respiratory infection that can lead to significant illness, hospitalisation and even death, particularly for those with certain underlying health conditions. GSK is proud to expand prevention options against RSV across Europe.”

 

---

---

Related Topics and Keywords

arexvy, GSK, RSV vaccine, rswv